Valuation: Morepen Laboratories Limited

Market Cap 18.52B 194M 169M 158M 145M 273M 278M 1.86B 728M 9.24B 730M 714M 30.46B P/E 2024
22.4x
P/E 2025 21.8x
Enterprise Value 18.52B 194M 169M 158M 145M 273M 278M 1.86B 728M 9.24B 730M 714M 30.46B EV / Sales 2024
1.27x
EV / Sales 2025 1.45x
Free-Float
56.3%
Yield 2024 *
-
Yield 2025 0.42%
1 day+20.00%
1 week+25.10%
Current month+21.28%
1 month+13.82%
3 months+64.71%
6 months+76.34%
Current year+68.44%
1 week 55
Extreme 55
69.18
1 month 51.38
Extreme 51.38
69.18
Current year 33.05
Extreme 33.05
69.18
1 year 33.05
Extreme 33.05
69.18
3 years 31.3
Extreme 31.3
100.9
5 years 23.6
Extreme 23.6
100.9
10 years 7.2
Extreme 7.2
100.9
Manager TitleAgeSince
Chief Executive Officer 58 2026-06-30
Chief Executive Officer 62 1992-01-31
Director of Finance/CFO 59 2002-04-02
Director TitleAgeSince
Chairman 62 1992-01-31
Director/Board Member 58 2019-08-12
Director/Board Member - 2020-06-21
Change 5-day change 1-year change 3-year change Capi.($)
+20.00%+25.10% - - 332M
-2.39%-6.36%+47.10%+149.66% 1T
-0.76%-4.34%+52.04%+49.09% 613B
-2.33%-4.60%+25.55%+64.44% 433B
+1.15%-2.39%+40.82%+35.48% 350B
+1.20%-3.54%+32.99%+41.21% 292B
+2.03%-9.46%+5.21%+7.39% 239B
+2.41%-7.77%-1.17%-41.72% 206B
-1.63%+0.69%+27.62%+64.23% 204B
+0.72%+0.48%+15.88%+73.64% 163B
Average +2.44%-3.88%+27.34%+49.27% 388.94B
Weighted average by Cap. +0.35%-4.34%+35.20%+71.54%

Financials

2024 2025
Net sales 17.02B 179M 155M 145M 133M 251M 255M 1.71B 669M 8.49B 671M 656M 27.99B 18.12B 190M 165M 154M 142M 267M 272M 1.82B 712M 9.03B 714M 698M 29.8B
Net income 962M 10.09M 8.77M 8.19M 7.51M 14.17M 14.42M 96.52M 37.8M 480M 37.89M 37.06M 1.58B 1.18B 12.38M 10.76M 10.05M 9.22M 17.39M 17.69M 118M 46.4M 589M 46.51M 45.48M 1.94B
Net Debt 121M 1.26M 1.1M 1.03M 942K 1.78M 1.81M 12.1M 4.74M 60.11M 4.75M 4.65M 198M -928K -9.74K -8.46K -7.9K -7.25K -13.67K -13.91K -93.15K -36.48K -463K -36.57K -35.76K -1.53M
Logo Morepen Laboratories Limited
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Employees
1,814
Date Price Change Volume
26-08-04 69.18 +20.00% 67,096,271
26-08-03 ₹57.65 +1.07% 5,950,210
26-07-31 ₹57.04 +1.10% 2,542,492
26-07-30 ₹56.42 -2.47% 3,524,842
26-07-29 ₹57.85 +4.61% 6,074,005